Analyst Note Rocks GE; Drug Stock Pops on FDA Nod

GE is trading just above its lows from earlier this month

Mar 13, 2018 at 1:53 PM
facebook twitter linkedin

Stocks have given back their early gains following the shake-up in President Trump's cabinet. Among individual names making notable moves are chipmaker Advanced Micro Devices, Inc. (NASDAQ:AMD), Dow component General Electric Company (NYSE:GE), and biotech Proteostasis Therapeutics Inc (NASDAQ:PTI). Here's a quick look at what's driving shares of AMD, GE, and PTI.

AMD Shares Ricochet Higher

AMD stock is in focus today after cybersecurity research firm CTS Labs published a report detailing multiple "severe security" flaws in the company's chips. However, as of last check the shares had pared earlier losses to trade up 1.5% at $11.70.

Advanced Micro Devices has been making big moves on the charts for months, and recently saw a boom in put trading. One indicator that stands out is AMD's Schaeffer's put/call open interest ratio (SOIR) of 1.40. Not only does this show put open interest outweighing call open interest among contracts expiring within three months, but it ranks just 2 percentage points from a 12-month high.

Bear Note Sinks GE Stock Again

General Electric shares are trading down 4.1% at $14.48 -- not far from their March 1 low of $13.95 -- after a price-target cut to $11 from $14 at J.P. Morgan Securities. The brokerage firm, which rates the stock at "underweight," said GE's dividend is "still high risk." The blue-chip stock has shed more than half its value over the past year.

Elsewhere, short interest has been tick-tocking higher since early 2017 -- yet less than 2% of the equity's float is sold short. This suggests there's plenty of room for short sellers to pile on.

Proteostasis Therapeutics Stock Jumps 53%

Proteostasis Therapeutics announced the Food and Drug Administration (FDA) has granted a breakthrough therapy designation to its cystic fibrosis drug. Shares of PTI were last seen up 53.2% at $6.34, making it the second best stock on the Nasdaq today. This move has the stock on pace for its highest close in almost a year, as the $6.40 level kept a tight lid on the last breakout attempt in December and January. Analysts certainly have high expectations, given Proteostasis' average 12-month price target of $14.75.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners